Phase 4 N=106 PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)
Liver Cirrhosis · Hypertension, Portal
Primary: Variceal Bleeding Events — 3; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=50 Wired Magnetically Assisted Capsule Endoscopy and Esophageal Varices
Esophageal Varices
Primary: Aerosol-generating Amount — 8195; 0; 13296; 1483 Particles generated
Phase 4 N=121 Carvedilol as an Adjunct to Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding
Esophageal and Gastric Varices
Primary: Rebleeding From Gastric Varices — 14; 21 Participants
Phase 4 N=90 Time Interval for Endoscopic Variceal Ligation
Variceal Bleeding
Primary: Proportion of Patients With Eradication of Esophageal Varices — 37; 23 Participants
N/A N=280 The SHUNT-V Study for Varices
Chronic Liver Disease
Primary: Disease Severity Index (DSI) Less Than/Equal to 18.3 to Rule Out Large Varices — 33; 3; 171; 68 Participants
N/A N=235 Doppler Ultrasound Probe for Blood Flow Detection in Severe Upper Gastrointestinal Hemorrhage
UGI Bleeding · Ulcer or Variceal Hemorrhage · Stigmata of Recent Hemorrhage
Primary: 30 Day Rebleeding Rate — 20; 8; 17; 6 Participants
Phase 4 N=1,034 Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding
Variceal Bleeding, Cirrhosis
Primary: 5-day Treatment Failure (Failure to Control Bleeding, Rebleeding, or Death) — 218; 216; 225 participants
N/A N=455 The Association With Peptic Ulcer Disease and Hepatic Vein Pressure Gradient
Cirrhosis · Chronic Liver Disease
Primary: The Association of HVPG and PUD in Patients With Liver Cirrhosis — 14.5; 15.3 mmHg
N/A N=109 Optical Coherence Tomography (OCT) Based Screening of Esophagus and Gastroesophageal Junction
Barrett's Esophagus
Primary: Number of Subjects in Which the Entire Distal Esophagus Can be Visualized Using the Balloon Based Optical Coherence Tomography Screening — 109 Participants
Phase 2 N=73 Endoscopic Therapy of Early Cancer in Barretts Esophagus
Early Stage Esophageal Adenocarcinoma · Barrett Esophagus
Primary: Level of Dysplasia on Histology at 12 Months — 10; 11; 15; 2 paricipants — p=0.0098
N/A N=93 Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment
Esophageal Lesion
Primary: Number of Participants With Esophageal Lesions Identified Using Capsule Endoscopy — 15 Participants
N/A N=47 Esophageal Deviation in Atrial Fibrillation Ablation
Atrial Fibrillation
Primary: Number of Participants With a Minimum Distance of 1 cm Esophageal Deviation Between the Ablation Line for the Ipsilateral Pulmonary Vein (PV) Pairs and the Trailing Edge…
N/A N=24 Capsule Endoscopy for HEmorrhage in the ER
Upper Gastrointestinal Bleeding
Primary: Number of Participants Discharged for Outpatient Management of Upper GI Bleeds — 3; 9 Participants
N/A N=26 Outcomes of Esophageal Self Dilation for Benign Refractory Esophageal Stricture Management
Esophageal Dilation · Refractory Benign Esophageal Stricture
Primary: Number of Endoscopic Interventions — 12; 11; 12; 7 endoscopies
N/A N=37 a/LCI-OCT Pilot in Esophagus
Barrett Esophagus
Primary: Percentage of Correctly Identified Positive (Dysplastic) Biopsies — 100.0 percentage of correct identifications
N/A N=156 Non-endoscopic Brushing of the Esophagus Using a Non-endoscopic Inflatable Balloon of the Esophagus in Screening for Barrett Esophagus
Barrett Esophagus
Primary: Number of Participants Reporting Each Category of Tolerance Assessed by the Tolerance Survey — 96; 31; 1; 121 number of participants
N/A N=6 Using Spectrally Encoded Confocal Microscopy (SECM) to Visualise the Esophagus Using an SECM Probe
Barrett's Esophagus
Primary: Number of Participants With Tolerability of the Procedure — 6 Participants
Phase 3 N=222 High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer
Bleeding Peptic Ulcer
Primary: Rate of Clinically Significant Rebleeding Within 72 Hours — 107; 101; 1; 6 participants
N/A N=96 Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia
ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Primary: Complete Response — 81 Participants
Phase 2 N=60 Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt
Varicose Veins
Primary: Patients With Circulating MCA Bubbles Present on MRI Who Had Signficant Clinical or Neurological Effects — 0 participants
N/A N=163 Evaluation of the Impact of a Forward Viewing Scope at Time of ERCP
Gastro-Intestinal Disorder
Primary: Number of Participants With Clinically Significant Endoscopic Findings — 37 Participants
N/A N=22 Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus
Barrett's Esophagus
Primary: Number of Subjects in Which the Targeted Locations Identified Through OFDI Imaging Correlates With the Biopsies. — 22 Participants
N/A N=100 Prospective Study to Compare the Efficacy of E.G.Scan to Detect Barrett's Esophagus Compared With Standard Endoscopy
Barrett's Esophagus
Primary: Median Tolerability Score on 10-point Visual Analog Scale (VAS) — 7; 8; 8; 8 units on a scale
N/A N=449 Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation
Esophagogastroduodenoscopy · Colonoscopy
Primary: Residual Gastric Volumes of Different Bowel Preparation Regimens — 19; 16; 18 mL
N/A N=3 Pilot Study to Image the Esophagus Using a SECM Tethered Endoscopic Capsule
Healthy · Barrett's Esophagus · Gastric Acid Reflux
Primary: Feasibility for Imaging of Esophagus Using an SECM Tethered Endoscopic Capsule. — 3 Participants
Phase 4 N=178 Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension
Liver Diseases · Portal Hypertension
Primary: Diagnostic Accuracy of SHAPE Liver Pressure Estimates (in dB) for Diagnosing Portal Hypertension With Catheter Pressure Measurements (in mmHg) as the Reference Standard…
Phase 2 N=64 FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: 6-month Progression-free Survival (PFS) — 60.5; 57.1 percent probability — p=0.72
N/A N=7 Evaluation of Pancreatobiliary Disorders in Patients With Altered Gastric Anatomy
Pancreatobiliary Disease · Altered Gastric Anatomy
Primary: Papilla or Duct-enterostomy Was Reached — 10 ERCPs
Phase 3 N=366 A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors
GERD
Primary: Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12…
N/A N=355 Evaluation of Endostapled Anastomoses for Laparoscopic Gastric Bypass (EEA-LGB)
Morbid Obesity
Primary: Number of Participants With Postoperative Gastrointestinal Hemorrhage — 13; 39 participants